Overview

• The Mass General Brigham–led, multi‑institutional team reported the findings in Science Translational Medicine using a longitudinal sampling platform.
• Researchers collected 96 tumor samples over four months from two recurrent GBM patients treated with the oncolytic virus CAN‑3110.
• Integrated multi‑omic profiling and AI‑enabled digital pathology detected therapy‑driven immune responses and remodeling of the tumor microenvironment.
• MRI scans suggested progression consistent with pseudoprogression, yet tissue analyses showed a pathologic response in one patient and stable disease in the other.
• Investigators are continuing enrollment toward 12 patients and plan to apply the serial‑sampling approach to additional vaccine immunotherapies to validate and extend the results.